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Abstract
Depressive symptoms have debilitating effects on the physical health and functioning of people 
with serious mental illness. We examined change in depressive symptoms among overweight and 
obese adults with serious mental illness (n=343) using data combined from two randomized trials 
comparing the 12-month In SHAPE program to a gym membership control condition. In SHAPE 
consists of a gym membership, weekly individual meetings with a fitness trainer, and instruction 
on healthy eating and nutrition. Depressive symptoms were measured at baseline, 3-, 6-, and 12-
months. Change in depressive symptoms did not differ between groups, but depressive symptoms 
decreased over time across the entire sample (p=0.045). At 12-months, reduced depressive 
symptoms were associated with clinically significant improved cardiorespiratory fitness (p=0.030), 
≥10% weight loss (p=0.044), and cardiovascular risk reduction (p=0.028) across both groups. Our 
findings suggest that participation in health promotion programs resulting in cardiovascular risk 
reduction may be associated with reduced depressive symptoms.
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Introduction
Obesity prevalence is nearly double among people with serious mental illness, including 
schizophrenia spectrum and mood disorders, compared to the general population (Dickerson 
et al., 2006). As a result, people with serious mental illness are at high risk for 
cardiometabolic disorders and experience dramatic reduction in life expectancy (Walker, 
McGee, & Druss, 2015). Numerous challenges interfere with treating obesity in this at-risk 
group, including metabolic effects of psychiatric medications, low motivation, poverty, and 
limited access to safe and affordable options for physical activity (Allison et al., 2009). 
Studies in the general population show a strong association between elevated obesity and 
more frequent and severe depressive symptoms (Onyike, Crum, Lee, Lyketsos, & Eaton, 
2003; Strine et al., 2008). This is a potentially significant concern, because people with 
serious mental illness experience elevated depressive symptom severity across diagnostic 
groups (Mechanic, McAlpine, Rosenfield, & Davis, 1994).
Among people with serious mental illness, depressive symptoms are associated with greater 
disability (Meesters et al., 2014), poor physical health (Sajatovic et al., 2015), and elevated 
risk of substance use (Kerfoot et al., 2011). Depressive symptoms also contribute to poor life 
satisfaction (Fervaha, Agid, Takeuchi, Foussias, & Remington, 2013; Mechanic et al., 1994). 
Research highlights that low motivation and low satisfaction with life are predictors of 
unhealthy habits including poor diet and physical inactivity (Vancampfort et al., 2012). 
Therefore, the co-occurrence of elevated obesity and depressive symptoms among people 
with serious mental illness likely exacerbates cardiovascular risk factors and may present 
additional challenges to adopting healthy lifestyle behaviors.
Lifestyle interventions have emerged as effective for targeting obesity and poor health 
behaviors among people with serious mental illness and appear promising for addressing 
modifiable risk factors such as poor cardiorespiratory fitness that are linked to early 
mortality (McGinty, Baller, Azrin, Juliano-Bult, & Daumit, 2016; Vancampfort, Rosenbaum, 
Schuch, Ward, Richards, et al., 2016). Recent randomized trials of interventions focused on 
promoting exercise and healthy eating have achieved clinically significant weight loss in 
upwards of 47% of participants, or reduced cardiovascular risk through improved 
cardiorespiratory fitness and weight loss in as many as half of participants with serious 
mental illness (Bartels et al., 2013; Bartels et al., 2015; Daumit et al., 2013; Green et al., 
2015). Little is known about whether participation in evidence-based lifestyle interventions 
implemented in real world community mental health settings can also contribute to reduction 
in depressive symptoms in this at-risk group.
Prior studies suggest that intensive lifestyle interventions aimed at achieving weight loss 
through healthy eating, caloric restriction, and increased exercise can lead to reduction in 
depressive symptoms among people with diabetes from the general population 
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(Faulconbridge et al., 2012; Look AHEAD Research Group, 2014) and obese individuals 
with clinical depression (Linde et al., 2011). Among people with serious mental illness, a 
pilot study of a behavioral weight loss intervention reported a reduction in depressive 
symptoms over a 6-month period (Daumit et al., 2011), though another pilot study found no 
change in depressive symptoms over a comparable duration (Van Citters et al., 2010). 
Lifestyle interventions for people with serious mental illness may offer promise for 
improving other health-related outcomes in addition to weight loss, including increased self-
efficacy and more positive perceptions of body image (Yarborough et al., 2015), as well as 
improved self-perceived health status (Temmingh et al., 2013). Given the combined impact 
of depression and obesity on cardiovascular risk and early mortality, it is important to further 
investigate the impact of lifestyle interventions targeting fitness and weight loss on 
depressive symptoms among people with serious mental illness.
The purpose of this study was to examine the impact of lifestyle intervention participation 
on change in depressive symptoms among overweight and obese adults with serious mental 
illness. We combined data from two randomized controlled trials to explore the differential 
effect on change in depressive symptoms over time of participation in the 12-month In 
SHAPE lifestyle intervention compared to participation in a gym membership group. The In 
SHAPE program consists of a gym membership, weekly individual meetings with a fitness 
trainer, and instruction on healthy eating and nutrition. We hypothesized that the In SHAPE 
intervention group would show greater reduction in depressive symptoms compared to the 
gym membership comparison group, because of the additional support for engaging in 
physical activity provided by the fitness trainer. Additionally, given the established link 
between depressive symptoms and poor physical health, we also explored whether clinically 
significant improvement in cardiorespiratory fitness, weight loss, and cardiovascular risk 




The analyses in this study used pooled data from 343 participants with serious mental illness 
enrolled in two randomized trials comparing the 12-month In SHAPE lifestyle intervention 
to a gym membership comparison group. In the first randomized trial (N=133), conducted 
from April 2007 to November 2011 (registered at clinicaltrials.gov: NCT02334228), 
participants were randomly assigned to the In SHAPE lifestyle intervention or to gym 
membership at one community mental health center in Concord, New Hampshire (Bartels et 
al., 2013). In the second randomized trial (N=210), conducted from April 2008 to May 2013 
(registered at clinicaltrials.gov: NCT02090335), participants were randomly assigned to the 
In SHAPE lifestyle intervention or to gym membership across three community mental 
health centers in Boston, Massachusetts (Bartels et al., 2015).
Participants in both trials were age 21 or older; had serious mental illness defined by an axis 
I diagnosis of major depressive disorder, bipolar disorder, schizoaffective disorder, or 
schizophrenia (based on the Structured Clinical Interview for DSM–IV), and persistent 
impairment in multiple areas of functioning (e.g., work, school, self-care) (First, Spitzer, 
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Gibbon, & Williams, 1995); had body mass index (BMI) greater than 25; and provided 
informed consent for participation. Participants were on stable pharmacological treatment, 
defined as receiving the same psychiatric medications over the 2 months prior to enrollment.
The design and methods, and detailed inclusion and exclusion criteria, are reported 
elsewhere (Bartels et al., 2013; Bartels et al., 2015). The randomized trials evaluated the 
effect of the In SHAPE lifestyle intervention compared to the gym membership comparison 
group on weight loss and improved fitness. Roughly half of participants receiving In SHAPE 
in each study, 49% (Bartels et al., 2013) and 51% (Bartels et al., 2015), achieved 
cardiovascular risk reduction defined as clinically significant weight loss or improved 
cardiorespiratory fitness. Committees for the Protection of Human Subjects at Dartmouth 
College and specific to each site approved all study procedures.
In SHAPE Program
In SHAPE is a 12-month lifestyle intervention consisting of a gym membership, weekly 
individual meetings with a certified fitness trainer, and instruction on healthy eating and 
nutrition. The fitness trainers completed a one-week In SHAPE training consisting of 
instruction in motivational interviewing, fitness goal setting, healthy nutrition, methods for 
tracking eating and exercise, and strategies for supporting health behavior change among 
people with serious mental illness, such as addressing mental health symptoms that interfere 
with exercise and healthy eating. Prior to enrollment, participants obtained medical 
clearance for exercise from their primary care provider. After conducting lifestyle and fitness 
evaluations, the fitness trainer developed personalized fitness plans for each participant using 
shared goal setting. Thereafter, they met with participants individually each week for 45–60 
minutes at a local gym (YMCA) and provided fitness coaching, support, and reinforcement 
for exercise. The nutrition component consisted of individualized instruction during each 
session emphasizing healthy eating. Throughout the program the fitness trainers received 
ongoing supervision from a health psychologist, a personal fitness trainer, and a registered 
dietitian.
Gym Membership Comparison Group
The comparison condition consisted of a gym membership to the same local gym as the In 
SHAPE group (YMCAs) with an introduction in safe use of the exercise equipment.
Measures
Trained interviewers collected outcome measures at baseline, and at 3 months, 6 months, 
and 12 months. The interviewers were blind to group assignment. Depressive symptoms 
were measured using the Center for Epidemiological Studies Depression (CESD) scale. The 
CESD is a 20-item self-report depression symptom scale, with scores ranging from 0 to 60, 
where higher scores represent higher levels of depression (Radloff, 1977). The CESD has 
well-documented psychometric properties in psychiatric populations (Weissman, 
Sholomskas, Pottenger, Prusoff, & Locke, 1977).
Clinically significant improved cardiorespiratory fitness was calculated as the proportion of 
participants who achieved an increase in distance >50 meters (about 164 feet) on the 6-
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Minute Walk Test (6-MWT) at 12-months. The 6-MWT measures the distance in meters that 
an individual can walk in six minutes and is a reliable and valid measure of cardiorespiratory 
fitness (Beriault et al., 2009). An increase of at least 50 meters is considered clinically 
significant, because it is associated with a reduction in cardiovascular risk (Rasekaba, Lee, 
Naughton, Williams, & Holland, 2009). Cardiorespiratory fitness is an important modifiable 
risk factor for cardiovascular disease, and a recent meta-analysis demonstrated that physical 
activity participation may contribute to improved cardiorespiratory fitness among people 
with schizophrenia (Vancampfort, Rosenbaum, et al., 2015).
Clinically significant weight loss was measured at 12-months using two different 
approaches. First, we calculated the proportion of participants who achieved ≥5% weight 
loss, because modest weight loss is associated with reduction in cardiovascular risk among 
overweight and obese individuals (Van Gaal, Wauters, & De Leeuw, 1997; Wing et al., 
2011). We also calculated the proportion of participants who achieved ≥10% weight loss, 
because weight loss of this magnitude is associated with improvements in risk factors for 
heart disease and diabetes (Wing & Phelan, 2005).
We also collected data on participants’ medication use, but not dosage. Different psychiatric 
medications can have an impact on mood and depressive symptoms (Siris, 2000), are 
associated with varying degrees of weight gain (Allison et al., 1999; Taylor & McAskill, 
2000), and are known to affect ability to lose weight (Allison et al., 2009). We classified 
participants’ medications as high weight gain propensity (e.g., olanzapine and clozapine), 
medium weight gain propensity (e.g., risperidone), or low weight gain propensity (e.g., 
ziprasidone). We also used a binary (Yes/No) variable to code participants’ medications as 
antidepressants (e.g., duloxetine, fluoxetine, bupropion, or sertraline) or not according to the 
Food and Drug Administration’s classification system.
Statistical Analysis
Participants in the In SHAPE lifestyle intervention were compared with participants in the 
gym membership condition at baseline on demographic characteristics, mental health 
diagnoses, obesity measures, fitness, use of antidepressant and psychiatric medications, and 
depressive symptoms using chi-square tests for categorical variables and t-tests for 
continuous variables. The impact of the In SHAPE intervention on depressive symptoms 
was examined using mixed-effects longitudinal regression models, controlling for study 
(RCT 1 or RCT 2), treatment group × time interaction, age, gender, mental health diagnosis, 
race, and use of antidepressant medications. Depressive symptoms were measured at four 
time points. Models included participant-level random intercept and random slope to allow 
for individual-level trajectories and account for repeated observations within individual. To 
determine whether depressive symptoms changed over time across both groups, the time 
effect was examined. To assess whether change in depressive symptoms differed between 
the In SHAPE and gym membership groups, according to our primary hypothesis, the 
treatment group × time interaction effect was examined. Analyses were intent-to-treat and 
included all randomized participants according to intervention assignment. We controlled for 
trial (RCT 1 or RCT 2) to account for the possibility that participants enrolled in one trial 
were more similar to each other than individuals recruited in the other trial. To explore 
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whether there was an association between clinically significant outcomes of improved 
fitness (>50 meter increase on the 6-MWT), weight loss (≥5% and ≥10%), and 
cardiovascular risk reduction (defined as ≥5% weight loss or >50 meter increase on the 6-
MWT) and change in depressive symptoms at 12-months, we used linear regression models 
controlling for treatment group, study (RCT 1 or RCT 2), age, gender, mental health 
diagnosis, race, and use of antidepressant medications. All analyses were performed using 
Stata 14 software, and p-values less than 0.05 are considered statistically significant.
Results
Baseline characteristics for the 343 participants enrolled in both trials are listed in Table 1. 
Participants had a schizophrenia spectrum (46%) or mood disorder (54%), a mean age of 
43.8±11.3 years, and were predominantly non-Hispanic white (62%). Baseline BMI was 
37.1±8.2 kg/m2. There were no differences between In SHAPE participants and gym 
membership participants on any characteristics except for marital status. More In SHAPE 
participants were never married, while more gym membership participants were previously 
married.
In total, 80% of participants completed 12-month assessments. The proportion of In SHAPE 
participants (81%) and gym membership participants (78%) who completed 12-month 
assessments was comparable. Participants lost to follow-up did not differ from participants 
who completed 12-month assessments on any baseline characteristics.
Table 2 shows the change in depressive symptoms over time between the In SHAPE and 
gym membership control groups. A decrease in depressive symptoms, measured using the 
CESD, was observed among both In SHAPE and gym membership participants over time as 
illustrated by the statistically significant time effect (p = 0.045). There were no between-
group differences as reflected by the non-significant group × time interaction (p = 0.475).
Table 3 shows the association between clinically significant outcomes and change in 
depressive symptoms at 12-months across the entire study sample. Clinically significant 
improved fitness defined as >50 meter increase on the 6-MWT was associated with a 
reduction in depressive symptoms (p = 0.030). The relationship between ≥5% weight loss 
and change in depressive symptoms was not significant (p = 0.107), but ≥10% weight loss 
was associated with significant reduction in depressive symptoms (p = 0.044). Reduction in 
cardiovascular risk, defined as ≥5% weight loss or >50 meter increase on the 6-MWT, was 
significantly associated with a decrease in depressive symptoms (p = 0.028). Over the 12-
month study duration, In SHAPE participants had an average of 27.0±13.2 visits with the 
fitness trainer, a value that was not associated with change in depressive symptoms (p = 
0.098).
Discussion
We found that depressive symptoms decreased significantly over a 12-month period for our 
entire sample of overweight and obese adults with serious mental illness randomized to 
either the In SHAPE intervention or gym membership comparison group. Contrary to our 
initial hypothesis, the addition of weekly individual visits with a fitness trainer in the In 
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SHAPE program did not appear to result in further reduction in depressive symptoms 
beyond what was obtained from access to a gym membership. It is possible that providing 
free access to a community fitness facility contributed to the observed reduction in 
depressive symptoms. Prior studies have shown that participation in exercise programs of 
varying intensity can lead to fewer depressive symptoms among people with mental illness 
(Meyer, Koltyn, Stegner, Kim, & Cook, 2016; Stubbs, Rosenbaum, Vancampfort, Ward, & 
Schuch, 2016). However, a recent systematic review and meta-analysis of 41 randomized 
controlled trials of exercise interventions for adults with depression or major depressive 
disorder found that the control groups achieved significant improvement in depressive 
symptoms (Stubbs, Vancampfort, et al., 2016). Therefore, it is possible that we may have 
similarly observed a control group response in the form of reduction in depressive symptoms 
regardless of whether or not participants were provided access to a gym membership. As 
previously reported, the In SHAPE lifestyle intervention contributed to greater weight loss 
(Bartels et al., 2015) and improved cardiorespiratory fitness (Bartels et al., 2013) when 
compared to a gym membership only comparison group.
We also found that clinically significant improved cardiorespiratory fitness, ≥10% weight 
loss, and reduction in cardiovascular risk at 12-months were associated with significant 
reduction in depressive symptoms among participants in the In SHAPE program and gym 
membership comparison group. This suggests that health promotion efforts targeting weight 
loss and fitness may also contribute to reduced depressive symptoms. Our findings are 
consistent with prior studies that have demonstrated that depressive symptoms are inversely 
correlated with cardiorespiratory fitness among people with serious mental illness 
(Papasavvas, Bonow, Alhashemi, & Micklewright, 2016). The implications are important 
because people with serious mental illness experience an elevated burden of cardiovascular 
disease largely due to modifiable lifestyle behaviors such as physical inactivity and poor diet 
(McGinty et al., 2016). Epidemiologic studies have found associations between depressed 
mood and high rates of poor health behaviors, including physical inactivity, unhealthy 
eating, heavy drinking, inadequate sleep, and smoking (Allgöwer, Wardle, & Steptoe, 2001; 
Frederick, Frerichs, & Clark, 1988; Strine et al., 2008). Additionally, symptoms of 
depression have been identified as a significant predictor of cardiovascular events, with the 
relationship largely explained by associated behavioral factors such as physical inactivity 
(Whooley et al., 2008).
For people with serious mental illness, depressive symptoms are known to negatively impact 
participation in physical activity. Depressive symptoms were identified as a barrier to 
engaging in physical activity among people with schizophrenia (Stubbs, Firth, et al., 2016), 
and more frequent occurrence and longer duration of depressive symptoms were associated 
with sedentary behaviors among people with bipolar disorder (Sylvia et al., 2013). Another 
study found that worse performance on the 6-MWT was associated with more severe 
depressive symptoms among people with bipolar disorder (Vancampfort, Wyckaert, et al., 
2015). In a mixed methods study, people with serious mental illness reported that mental 
health concerns such as depressive symptoms were the main reason for not participating in 
physical activity (Shor & Shalev, 2016).
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Despite this observed relationship between depressive symptoms, poor health behaviors and 
increased cardiovascular risk, exercise interventions offer promise for addressing both 
mental and physical health concerns. A systematic review and meta-analysis of 90 
randomized trials found that exercise training for people with chronic health conditions from 
general patient populations contributed to improvement in depressive symptoms, and this 
improvement was significantly associated with important functional and clinical outcomes 
such as improved fitness and reduced cardiovascular risk (Herring, Puetz, O’Connor, & 
Dishman, 2012). Our findings expand on these studies by demonstrating that if enrolling in 
interventions aiming to increase physical activity participation and cardiorespiratory fitness 
can achieve clinically significant reduction in cardiovascular risk among the high-risk group 
of people with serious mental illness, then it may also alleviate the depressive symptoms that 
can be associated with poor lifestyle habits. To our knowledge, this is the first study to 
demonstrate this finding among people with serious mental illness enrolled in a lifestyle 
intervention for weight loss. Importantly, our study also contributes to mounting evidence 
showing that efforts to promote exercise can contribute to improved cardiorespiratory fitness 
among people with serious mental illness (Vancampfort, Rosenbaum, Schuch, Ward, 
Richards, et al., 2016).
Important strengths of our study include the relatively large sample size and use of both rural 
and urban community mental health centers. We also observed high participant retention 
across both groups. When considering a recent review of participant dropout from physical 
activity interventions for people with serious mental illness (Vancampfort, Rosenbaum, 
Schuch, Ward, Probst, et al., 2016), it is possible that high participant retention in our study 
may have been due in part to the use of certified fitness trainers in the In SHAPE program 
and an active control condition consisting of access to a gym membership.
Several limitations should also be noted. First, our findings may not generalize to individuals 
with serious mental illness who are not enrolled in treatment or to those who are not 
interested in participating in lifestyle interventions involving physical activity. Second, it is 
important to note that while the observed reduction in depressive symptoms was statistically 
significant, this change was small and it is not clear whether it translates to other meaningful 
improvements in quality of life or functioning in participants’ daily lives. Third, it is not 
possible to determine the direction of the relationship between reduced depressive symptoms 
and clinically significant improved cardiorespiratory fitness, weight loss, and cardiovascular 
risk reduction. Fourth, use of an active control group may have contributed to the observed 
reduction in depressive symptoms. However, we were unable to collect data on the 
frequency of visits to the gym, therefore we are unable to determine whether use of the gym 
was associated with reduction in depressive symptoms across both the intervention and 
control groups. Fifth, while we believe that the reduction in depressive symptoms is not 
reflective of regression to the mean, because this change was associated with objectively 
measured weight and fitness outcomes, it is not possible to rule out such temporal 
influences. Lastly, longer-term follow-up is necessary to determine whether reduction in 
depressive symptoms associated with clinically meaningful cardiovascular risk reduction is 
sustained over time.
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People with serious mental illness experience elevated burden of depressive symptoms that 
have negative consequences on their physical health, functioning, and likelihood to adopt 
healthy behaviors. Our findings suggest that health promotion efforts that can achieve 
clinically significant reduction in cardiovascular risk through weight loss or improved 
cardiorespiratory fitness may also contribute to a reduction in depressive symptoms in this 
at-risk group. Future studies must determine whether these mental health benefits are 
sustained long term and whether these benefits contribute to other meaningful improvements 
in functioning, quality of life, and participation in daily activities. Research is also necessary 
to explore whether incorporating focused depression treatment into lifestyle programs such 
as In SHAPE could enhance the effectiveness of these programs for achieving clinically 
meaningful reduction in cardiovascular risk. The poor mental and physical health of people 
with serious mental illness and resulting early mortality represents a significant public health 
concern. Combined efforts spanning research, clinical practice, and policy must continue to 
work towards implementing evidence-based lifestyle interventions in community mental 
health settings aimed at addressing the health needs of this at-risk group. The results from 
our study provide additional compelling evidence necessary to support these efforts.
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Table 1
Baseline characteristics of participants in the In SHAPE intervention group and the gym membership 
comparison group
Characteristic Total Sample In SHAPE Program Gym Membership p-valuea
n 343 171 172
Age, years (M ± SD) 43.8 ± 11.3 43.8 ± 11.5 43.9 ± 11.2 0.984
Sex 0.177
  Male 154 (45%) 83 (49%) 71 (41%)
  Female 189 (55%) 88 (51%) 101 (59%)
Race 0.106
  Black 72 (21%) 34 (20%) 38 (22%)
  Hispanic 31 (9%) 22 (13%) 9 (5%)
  Non-Hispanic white 212 (62%) 102 (60%) 110 (64%)
  Other 28 (8%) 13 (8%) 15 (9%)
Education 0.619
  Less than high school 51 (15%) 28 (16%) 23 (13%)
  High school 105 (31%) 49 (29%) 56 (33%)
  Greater than high school 187 (55%) 94 (55%) 93 (54%)
Current Smoker 149 (43%) 72 (42%) 77 (45%) 0.619
Living Situation 0.421
  Living Independent 229 (67%) 118 (69%) 111 (65%)
  Supervised/Supported
  Housing
113 (33%) 53 (31%) 60 (35%)
Married 0.007
  Never Married 209 (61%) 118 (69%) 91 (53%)
  Currently Married 25 (7%) 8 (5%) 17 (10%)
  Previously Married 109 (32%) 45 (26%) 64 (37%)
Diagnosis 0.954
  Schizophrenia Spectrum
  Disorder
159 (46%) 79 (46%) 80 (47%)
  Mood Disorder 184 (54%) 92 (54%) 92 (54%)
BMI, kg/m2 (M ± SD)b 37.1 ± 8.2 36.4 ± 7.6 37.8 ± 8.6 0.107
Weight, pounds (M ± SD) 234.0 ± 54.3) 230.0 ± 52.1 237.9 ± 56.4 0.179
Fitness (M ± SD)c
CESD (M ± SD)d 22.6 ± 13.0 22.5 ± 12.6 22.8 ± 13.3 0.849
Medications
Antidepressant medication usee 187 (58%) 92 (58%) 95 (59%) 0.784
Number of antipsychotic
medications (M ± SD)
2.0 ± 1.1 2.1 ± 1.1 2.0 ± 1.0 0.573
Weight Gain Propensity 0.113
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Characteristic Total Sample In SHAPE Program Gym Membership p-valuea
  Highf 86 (27%) 49 (31%) 37 (23%)
  Mediumg 137 (43%) 67 (42%) 70 (44%)
  Lowh 77 (24%) 31 (40%) 46 (29%)
  None 19 (6%) 12 (8%) 7 (4%)
a
We compared means using t-tests and proportions using chi-square tests
b
Body Mass Index (BMI) was measured as kg/m2, with >25 kg/m2 indicating overweight or obesity.
c
Fitness was measured using the 6-Minute Walk Test (6-MWT), which measures the number of meters that an individual can walk in 6 minutes. 
Higher values indicate better fitness.
d
The Center for Epidemiological Studies Depression (CESD) is a 20-item self-report depression symptom scale, with scores ranging from 0 to 60, 
where higher scores represent higher levels of depression.
e
Antidepressant medications were classified according to the Food and Drug Administration classification system
f
High weight gain propensity medications include: olanzapine, clozapine
g
Medium weight gain propensity medications include: haloperidol, risperidone, quetiapine, thioridazine, chlorpromazine, paroxetine, amitriptyline, 
divalproex, valproate, doxepin, lithium, carbamazepine, imipramine, gabapentin
h
Low weight gain propensity medications include: ziprasidone, perphenazine, fluphenazine, fluoxetine, buproprion, venlafaxine, molindone, 
lamotrigine, duloxetine, aripiprazole, fluvoxamine, trazodone, desipramine, loxapine, sertraline, escitalopram, clomipramine, nortriptyline, 
citalopram, paliperidone, topiramate, mirtazapine, lurasidone
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Table 3
Association between change in depressive symptoms and clinically significant fitness and weight loss 
outcomes from baseline to 12-months
Clinically significant outcomes β 95% CI pa
Fitness (>50 meter increase on the 6-MWT)b −4.39 −8.35 to −0.44 0.030
Weight loss (≥5%) −2.58 −5.72 to 0.55 0.106
Weight loss (≥10%) −4.38 −8.65 to −0.12 0.044
Cardiovascular risk reduction (≥5% or >50
meter increase on the 6-MWT)
−3.41 −6.45 to −0.37 0.028
a
P-values from linear regression models controlling for treatment group, study (RCT 1 or RCT 2), age, gender, mental health diagnosis, race, and 
use of antidepressant.
b
Fitness was measured using the 6-Minute Walk Test (6-MWT), which measures the number of meters that an individual can walk in 6 minutes. 
Higher values indicate better fitness.
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